.Nature Medicine, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of clients with HER2+ sophisticated bosom cancer and energetic or stable human brain metastases showed constant intracranial activity and also systemic efficiency of T-DXd.